No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicenter, double-blind, randomized, placebo-controlled study
Authors:
- Annemarie GrohAGAnnemarie Groh
Open Access
- 1 July 1999
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 42 (7) , 1386-1396
Abstract
Objective To investigate the effect of long‐term antibiotic treatment in patients with reactive arthritis (ReA) and undifferentiated oligoarthritis. Methods One hundred twenty‐six patients were treated with ciprofloxacin (500 mg twice a day) or placebo for 3 months, in a double‐blind, randomized study. Of these patients, 104 (48 treated with ciprofloxacin and 56 treated with placebo) were valid for clinical evaluation: 55 were diagnosed as having ReA with a preceding symptomatic urogenic or enteric infection and 49 as having undifferentiated oligoarthritis. These 2 groups were randomized separately. The triggering bacterium was sought by serology and/or culture. The percentage of patients in remission after 3 months of treatment was chosen as the primary efficacy parameter. Results A triggering bacterium could be identified in 52 patients (50%): Chlamydia trachomatis in 13, Yersinia in 14, and Salmonella in 25. No patient was positive for Campylobacter jejuni or for Shigella. No difference in outcome was found between treatment with ciprofloxacin or placebo in the whole group or in subgroups of patients with ReA or undifferentiated oligoarthritis. No difference was seen in patients with a disease duration Yersinia‐ or Salmonella‐induced arthritis but seemed to be better than placebo in Chlamydia‐induced arthritis. This difference was not significant, however, which might be due to the small sample size. Conclusion Long‐term treatment of ReA with ciprofloxacin is not effective; however, it might be useful in the subgroup of patients who have Chlamydia‐induced arthritis. This has to be proven in a bigger study focusing on patients with Chlamydia‐induced arthritis.Keywords
This publication has 38 references indexed in Scilit:
- Lack of correlation between the detection ofChlamydia trachomatis DNA in synovial fluid from patients with a range of rheumatic diseases and the presence of an antichlamydial immune responseArthritis & Rheumatism, 1998
- Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A department of veterans affairs cooperative studyArthritis & Rheumatism, 1996
- Comparison of synovial tissue and synovial fluid as the source of nucleic acids for detection of Chlamydia trachomatis by polymerase chain reactionArthritis & Rheumatism, 1996
- Amplification of plasmid and chromosome chlamydia dna in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathiesArthritis & Rheumatism, 1995
- The value of specific antibody detection and culture in the diagnosis of reactive arthritisClinical Rheumatology, 1993
- Double‐blind, placebo‐controlled study of three‐month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritisArthritis & Rheumatism, 1991
- A wider spectrum of spondyloarthropathiesSeminars in Arthritis and Rheumatism, 1990
- Yersinia Antigens in Synovial-Fluid Cells from Patients with Reactive ArthritisNew England Journal of Medicine, 1989
- CHLAMYDIA TRACHOMATIS AND REACTIVE ARTHRITIS: THE MISSING LINKThe Lancet, 1987
- Reiter's Syndrome and Reactive Arthritis in PerspectiveNew England Journal of Medicine, 1983